US signs deal for second-line smallpox ‘biodefense therapeutic’
BioFactura receives $67.4m contract to develop and manufacture its monoclonal antibody therapeutic to treat the smallpox virus.
Archives for October 2, 2019
Immunovant goes public after investment from HSAC
HSAC will acquire 100% of the shares of Immunovant, taking the biotech public with $100m in cash and a lead product that set to go through Phase II trials.
China and Russia collaborate to create biologics joint venture
Shanghai Pharma and Biocad established a joint venture to commercialize the latter’s portfolio of biosimilars and biologic treatments for the Chinese market.